Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition

Journal of Cellular Biochemistry

Volumn 114, Issue 4, 2013, Pages 854-863

  Shah, Reecha D ^a   Jagtap, Jayashree C ^a   Mruthyunjaya, S ^a   Shelke, Ganesh V ^a   Pujari, Radha ^a   Das, Gowry ^a   Shastry, Padma ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

APOPTOSIS; HDAC; NEUROBLASTOMA; SODIUM VALPROATE (VPA); STAUROSPORINE; SURVIVIN

Indexed keywords

CASPASE 3; ENTINOSTAT; HISTONE DEACETYLASE; ISOENZYME; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN KINASE B; STAUROSPORINE; SURVIVIN; VALPROIC ACID;

APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY TEST; DIPLOIDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SYNERGISM; ENZYME ACTIVATION; G2 PHASE CELL CYCLE CHECKPOINTS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; ISOENZYMES; NEUROBLASTOMA; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIDINES; STAUROSPORINE; VALPROIC ACID;

EID: 84874267423     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24422     Document Type: Article

References (40)

1. Azuhata T, Scott D, Takamizawa S, Wen J, Davidoff A, Fukuzawa M, Sandler A,. 2001. The inhibitor of apoptosis protein survivin is associated with high-risk behavior of neuroblastoma. J Pediatr Surg 36: 1785-1791.
2. Campbell LA, Seeger RC, Harris RE, Villablanca JG, Matthay KK,. 1993. Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma. J Clin Oncol 11: 623-629.
3. Chandele A, Prasad V, Jagtap JC, Shukla R, Shastry PR,. 2004. Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. Neoplasia 6: 29-40.
4. Chen J, Ghazawi FM, Bakkar W, Li Q,. 2006. Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Mol Cancer 5: 71.
5. Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL,. 2008 Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 153: 657-668.
6. Dejligbjerg M, Grauslund M, Litman T, Collins L, Qian X, Jeffers M, Lichenstein H, Jensen PB, Sehested M,. 2008. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells. Mol Cancer 7: 70.
7. Dosik GM, Rodriguez V, Benjamin RS, Bodey GP,. 1978. Neuroblastoma in the adult: Effective combination chemotherapy. Cancer 41: 56-63.
8. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA,. 2008. Valproic acid as epigenetic cancer drug: Preclinical, clinical and transcriptional effects on solid tumors. Cancer Treat Rev 34: 206-222.
9. Gotfryd K, Skladchikova G, Lepekhin EA, Berezin V, Bock E, Walmod PS,. 2010. Cell type-specific anti-cancer properties of valproic acid: Independent effects on HDAC activity and Erk1/2 phosphorylation. BMC Cancer 10: 383.
10. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T,. 2001. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20: 6969-6978.
11. Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG, Anderson KC,. 2007. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 138: 783-791.
12. Hřebačková J, Poljaková J, Eckschlager T, Hraběta J, Procházka P, Smutný S, Stiborová M,. 2009. Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells. Interdisc Toxicol 2 (3): 205-210.
13. Huang KF, Zhang GD, Huang YQ, Diao Y,. 2012. Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3K-AKT pathway. Int Immunopharmacol 12 (2): 334-341.
14. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA,. 2004. Abberant regulation of survivin by the RB/E2F family of proteins. J Biol Chem 279: 40511-40520.
15. Johannessen CU,. 2000. Mechanisms of action of valproate: A commentatory. Neurochem Int 37: 103-110.
16. Jones PA, Baylin SB,. 2002. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3: 415-428.
17. Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM, Sezer O, Heider U,. 2006. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 91: 248-251.
18. Kazantsev AG, Thompson LM,. 2008. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 7: 854-868.
19. Khan O, La Thangue NB,. 2012. HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications. Immunol Cell Biol 90: 85-94.
20. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, Qian X, Mills E, Berghs SC, Carey N, Finn PW, Collins LS, Tumber A, Ritchie JW, Jensen PB, Lichenstein HS, Sehested M,. 2008. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 409: 581-589.
21. Kushner BH, LaQuaglia MP, Bonilla MA, Lindsley K, Rosenfield N, Yeh S, Eddy J, Gerald WL, Heller G, Cheung NK,. 1994. Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol 12: 2607-2613.
22. Lindemann R, Johnstone R,. 2004. Histone deacetylase inhibitors: Promising candidates for chemotherapeutic drugs. Gene Ther Mol Biol 8: 61-74.
23. Lladser A, Sanhueza C, Kiessling R, Quest AF,. 2011. Is survivin the potential Achilles' heel of cancer ? Adv Cancer Res 111: 1-37.
24. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK,. 2001. Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1: 194-202.
25. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP,. 1999. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341: 1165-1173.
26. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB, Liu S,. 2002. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21: 2613-2622.
27. Mottet D, Castronovo V,. 2010. Histone deacetylases: Target enzymes for cancer therapy. Clin Exp Metastasis 25: 183-189.
28. Mühlethaler-Mottet A, Meier R, Flahaut M, Bourloud KB, Nardou K, Joseph JM, Gross N,. 2008. Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol Cancer 7: 55.
29. Papanikolaou V, Iliopoulos D, Dimou I, Dubos S, Kappas C, Kitsiou-Tzeli S, Tsezou A,. 2010. Survivin regulation by HER2 through NF-kappaB and c-myc in irradiated breast cancer cells. J Cell Mol Med 15 (7): 1542-1550.
30. Park JR, Eggert A, Caron H,. 2010. Neuroblastoma: Biology, prognosis, and treatment. Hematol Oncol Clin North Am 24: 65-86.
31. Park DS, Hwang KE, Shim H, Kim BR, Choi KH, Park SH, Park SD, Jeong ET, Kim HR,. 2012. Elevated survivin is associated with a poor response to chemotherapy and reduced survival in lung cancer with malignant pleural effusions. Clin Exp Metastasis 29 (2): 83-89.
32. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS,. 2001. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 276: 36734-36741.
33. Pinkel D, Pratt C, Holton C, James D, Jr., Wrenn E, Jr., Hustu HO,. 1968. Survival of children with neuroblastoma treated with combination chemotherapy. J Pediatr 73: 928-931.
34. Rasheed WK, Johnstone RW, Prince HM,. 2007. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 16: 659-678.
35. Santini V, Gozzini A, Ferrari G,. 2007. Histone deacetylase inhibitors: Molecular and biological activity as a premise to clinical application. Curr Drug Metab 8: 383-393.
36. Schmidt ML, Lukens JN, Seeger RC, Brodeur GM, Shimada H, Gerbing RB, Stram DO, Perez C, Haase GM, Matthay KK,. 2000. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study. J Clin Oncol 18: 1260-1268.
37. Tunnicliff G,. 1999. Actions of sodium valproate on the central nervous system. J Physiol Pharmacol 50: 347-365.
38. Valentini A, Gravina P, Federici G, Bernardini S,. 2007. Valproic acid induces apoptosis,p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol Ther 6: 185-191.
39. Zhang L, Wang G, Wang L, Song C, Leng Y, Wang X, Kang J,. 2012. VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin. Mol Cell Biochem 361 (1-2): 39-45.
40. Zhao P, Meng Q, Liu LZ, You YP, Liu N, Jiang BH,. 2010. Regulation of survivin by PI3K/Akt/p70S6K1 pathway. Biochem Biophy Res Commun 395: 219-224.